MX383011B - Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma. - Google Patents

Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.

Info

Publication number
MX383011B
MX383011B MX2017004760A MX2017004760A MX383011B MX 383011 B MX383011 B MX 383011B MX 2017004760 A MX2017004760 A MX 2017004760A MX 2017004760 A MX2017004760 A MX 2017004760A MX 383011 B MX383011 B MX 383011B
Authority
MX
Mexico
Prior art keywords
preparing same
heat sterilized
formula including
including chitosan
sterilized formula
Prior art date
Application number
MX2017004760A
Other languages
English (en)
Spanish (es)
Other versions
MX2017004760A (es
Inventor
Napoli Alessandro Di
Leila Yolanda Bossy
Original Assignee
Laboratoire Medidom Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Medidom Sa filed Critical Laboratoire Medidom Sa
Publication of MX2017004760A publication Critical patent/MX2017004760A/es
Publication of MX383011B publication Critical patent/MX383011B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/04—Oxygen-containing compounds
    • C08K5/05—Alcohols; Metal alcoholates
    • C08K5/053—Polyhydroxylic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/719—Pullulans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L3/00—Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
    • C08L3/12—Amylose; Amylopectin; Degradation products thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2201/00—Properties
    • C08L2201/10—Transparent films; Clear coatings; Transparent materials
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2201/00—Properties
    • C08L2201/54—Aqueous solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2017004760A 2014-10-29 2015-10-28 Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma. MX383011B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2014/073246 WO2016066195A1 (en) 2014-10-29 2014-10-29 Heat-sterilized formulation comprising chitosan and process of preparation thereof
PCT/IB2015/058300 WO2016067210A1 (en) 2014-10-29 2015-10-28 Heat-sterilized formulation comprising chitosan and process of preparation thereof

Publications (2)

Publication Number Publication Date
MX2017004760A MX2017004760A (es) 2017-07-26
MX383011B true MX383011B (es) 2025-03-13

Family

ID=51842529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004760A MX383011B (es) 2014-10-29 2015-10-28 Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.

Country Status (17)

Country Link
US (1) US10493155B2 (OSRAM)
EP (1) EP3212166B1 (OSRAM)
JP (1) JP6814133B2 (OSRAM)
KR (1) KR102421423B1 (OSRAM)
CN (1) CN107075174B (OSRAM)
CA (1) CA2965447C (OSRAM)
CO (1) CO2017003840A2 (OSRAM)
DK (1) DK3212166T3 (OSRAM)
ES (1) ES2857273T3 (OSRAM)
HR (1) HRP20201995T1 (OSRAM)
HU (1) HUE053432T2 (OSRAM)
MX (1) MX383011B (OSRAM)
PT (1) PT3212166T (OSRAM)
RS (1) RS61214B1 (OSRAM)
RU (1) RU2712271C2 (OSRAM)
SI (1) SI3212166T1 (OSRAM)
WO (2) WO2016066195A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
AU2017250509B2 (en) 2016-04-14 2023-03-02 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
US10576099B2 (en) 2016-10-21 2020-03-03 Covidien Lp Injectable scaffold for treatment of intracranial aneurysms and related technology
US11452783B2 (en) * 2017-02-14 2022-09-27 Gi Supply Tissue stain and use thereof
WO2020208418A1 (en) 2019-04-12 2020-10-15 Azura Ophthalmics Ltd. Compositions and methods for the treatment of contact lens discomfort
WO2021092619A1 (en) 2019-11-04 2021-05-14 Covidien Lp Systems and methods for treating aneurysms
JP7453036B2 (ja) * 2020-03-30 2024-03-19 株式会社ナリス化粧品 皮膚外用剤
CN114652866A (zh) * 2020-12-23 2022-06-24 上海其胜生物制剂有限公司 一种羧甲基几丁质溶液的湿热灭菌方法
US12364793B2 (en) 2021-03-16 2025-07-22 Covidien Lp Injectable biopolymer compositions and associated systems and methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659700A (en) * 1984-03-02 1987-04-21 Johnson & Johnson Products, Inc. Chitosan-glycerol-water gel
JPS6462302A (en) * 1987-09-01 1989-03-08 Nippon Suisan Kaisha Ltd Water-soluble chitosan salt and production thereof
JPH06107551A (ja) * 1992-09-30 1994-04-19 Hisamitsu Pharmaceut Co Inc 関節症治療剤
JPH07118304A (ja) * 1993-10-27 1995-05-09 Asahi Glass Co Ltd キトサン水溶液
US5420197A (en) * 1994-01-13 1995-05-30 Hydromer, Inc. Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives
WO1997007139A2 (en) 1995-08-17 1997-02-27 Novartis Ag Stabilized chitin derivative compounds
EP1128809B1 (en) * 1998-11-20 2004-12-29 Laboratoire Medidom S.A. Aqueous ophthalmic formulations comprising chitosan
JP5116129B2 (ja) * 2000-09-01 2013-01-09 日本水産株式会社 中性付近のキトサン水溶液の製造法
US20020119949A1 (en) * 2001-02-26 2002-08-29 Asa Hellman Prophylactic teat treatment
JP5102435B2 (ja) * 2002-10-08 2012-12-19 株式会社リコム キトサン含有多糖、その製造方法及び用途
WO2007073749A1 (en) * 2005-12-23 2007-07-05 Laboratoire Medidom S.A. Thermosetting neutralized chitosan composition forming a hydrogel, lyophilizate, and processes for producing the same
US9034348B2 (en) * 2006-12-11 2015-05-19 Chi2Gel Ltd. Injectable chitosan mixtures forming hydrogels
US20090142292A1 (en) * 2007-12-03 2009-06-04 Blackwell Richard I Method For The Mitigation of Symptoms of Dry Eye

Also Published As

Publication number Publication date
HUE053432T2 (hu) 2021-07-28
DK3212166T3 (da) 2021-02-22
SI3212166T1 (sl) 2021-01-29
EP3212166A1 (en) 2017-09-06
RU2017118261A3 (OSRAM) 2019-04-25
WO2016067210A1 (en) 2016-05-06
CO2017003840A2 (es) 2017-04-28
RU2712271C2 (ru) 2020-01-28
CA2965447C (en) 2022-05-31
RU2017118261A (ru) 2018-11-29
ES2857273T3 (es) 2021-09-28
CA2965447A1 (en) 2016-05-06
PT3212166T (pt) 2021-02-09
KR20170076659A (ko) 2017-07-04
US10493155B2 (en) 2019-12-03
WO2016066195A1 (en) 2016-05-06
HRP20201995T1 (hr) 2021-02-05
BR112017008353A2 (pt) 2017-12-19
CN107075174A (zh) 2017-08-18
CN107075174B (zh) 2021-03-30
JP2017533186A (ja) 2017-11-09
US20170312364A1 (en) 2017-11-02
EP3212166B1 (en) 2020-12-02
KR102421423B1 (ko) 2022-07-15
RS61214B1 (sr) 2021-01-29
JP6814133B2 (ja) 2021-01-13
MX2017004760A (es) 2017-07-26

Similar Documents

Publication Publication Date Title
CO2017003840A2 (es) Formulación esterilizada por calor que comprende quitosán y proceso para preparación de la misma
PH12021550792A1 (en) 2-(morpholin-4-yl)-1,7-naphthyridines
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
CL2018000039A1 (es) Derivados de oxopiridina sustituidos
BR112017005104A2 (pt) derivado de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina
MX394266B (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
MX2017015881A (es) Formulaciones para vacunas contra la neoplasia y metodos para preparar las mismas.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX386256B (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX2016002238A (es) Alcoholes de alquilino y metodos de uso.
IN2013MU01749A (OSRAM)
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
MX2016002241A (es) Alcoholes de alquinilo y metodos de uso.
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
PH12017500207A1 (en) Indoles for use in influenza virus infection
PH12016501807A1 (en) Novel compounds
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
MX2016010328A (es) Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
MA43650B1 (fr) Formulations/compositions comprenant un inhibiteur de btk
TN2016000435A1 (en) Novel macrocyclic compounds.
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
BR112017016084A2 (pt) composição e método para o tratamento da doença veno-oclusiva hepática